Dried blood spots in HIV monitoring: Applications in resource-limited settings

Bioanalysis

Volumn 2, Issue 11, 2010, Pages 1893-1908

  Johannessen, Asgeir ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANALYTICAL EQUIPMENT; ANTIVIRAL RESISTANCE; BLOOD SAMPLING; DRIED BLOOD SPOT SAMPLING; DRUG MONITORING; GENETIC VARIABILITY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF QUANTITATION; NEWBORN SCREENING; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PLASMA; POLYMERASE CHAIN REACTION; PROCESS OPTIMIZATION; REVIEW; VIRUS LOAD; BLOOD; BLOOD ANALYSIS; DESICCATION; DRUG EFFECT; GENETICS; HEALTH CARE PLANNING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; BLOOD CHEMICAL ANALYSIS; BLOOD SPECIMEN COLLECTION; DESICCATION; DRUG MONITORING; HEALTH RESOURCES; HIV; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 79952511233     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.120     Document Type: Review

References (74)

1. Joint United Nations Program on HIV/AIDS (UNAIDS), World Health Organization (WHO). AIDS Epidemic Update: December 2009. UNAIDS, Geneva, Switzerland (2009).
2. Zwahlen M, Harris R, May M et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int. J. Epidemiol. 38(6), 1624-1633 (2009).
3. World Health Organization (WHO). Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. WHO, Geneva, Switzerland (2009).
4. Bussmann H, Wester CW, Ndwapi N et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22(17), 2303-2311 (2008).
5. Nash D, Katyal M, Brinkhof MW et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative ana lysis of prospective studies. AIDS 22(17), 2291-2302 (2008).
6. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19(18), 2141-2148 (2005). (Pubitemid 41669003)
7. Palombi L, Marazzi MC, Voetberg A, Magid NA) Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 21(Suppl 4), S65-S71 (2007). (Pubitemid 47051751)
8. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300(5), 555-570 (2008).
9. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. EACS, Paris, France (2009).
10. Cozzi-Lepri A, Phillips AN, Ruiz L et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 21(6), 721-732 (2007). (Pubitemid 46568629)
11. + cell counts and HIV RNA levels during follow-up. J. Infect. Dis. 197(8), 1145-1155 (2008). (Pubitemid 351590050)
12. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. WHO, Geneva, Switzerland (2006).
13. World Health Organization (WHO). Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. WHO, Geneva, Switzerland (2009).
14. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South AfricA) AIDS 22(15), 1971-1977 (2008).
15. van Oosterhout JJ, Brown L, Weigel R et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteriA) Trop. Med. Int. Health 14(8), 856-861 (2009).
16. Hosseinipour MC, van Oosterhout JJ, Weigel R et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing frst-line antiretroviral therapy. AIDS 23(9), 1127-1134 (2009).
17. h Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
18. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of flter paper for the collection and ana lysis of human whole-blood specimens. J. Nutr. 131(5), 1631S-1636S (2001). (Pubitemid 32422996)
19. Sherman GG, Stevens G, Jones SA, Horsfeld P, Stevens WS. Dried-blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J. Acquir. Immune Defc Syndr. 38(5), 615-617 (2005). (Pubitemid 40524486)
20. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359(21), 2233-2244 (2008).
21. Alvarez-Munoz M, Zaragoza-Rodriguez S, Rojas-Montes O et al. High correlation of human immunodefciency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions. Arch. Med. Res. 36(4), 382-386 (2005). (Pubitemid 40798393)
22. Andreotti M, Pirillo M, Guidotti G et al. Correlation between HIV-1 viral load quantifcation in plasma, dried-blood spots and dried-plasma spots using the Roche COBAS Taqman assay. J. Clin. Virol. 47(1), 4-7 (2010).
23. Ayele W, Schuurman R, Messele T et al. Use of dried spots of whole-blood, plasma and mother's milk collected on flter paper for measurement of human immunodefciency virus type 1 burden. J. Clin. Microbiol. 45(3), 891-896 (2007). (Pubitemid 46427707)
24. Brambilla D, Jennings C, Aldrovandi G et al. Multicenter evaluation of use of dried-blood and plasma-spot specimens in quantitative assays for human immunodefciency virus RNA: measurement, precision, and RNA stability. J. Clin. Microbiol. 41(5), 1888-1893 (2003). (Pubitemid 36576508)
25. Van Deursen P, Oosterlaken T, Andre P et al. Measuring human immunodefciency virus type 1 RNA loads in dried-blood spot specimens using NucliSENS® EasyQ HIV-1 v2.0. J. Clin. Virol. 47(2), 120-125 (2010).
26. Fiscus SA, Brambilla D, Grosso L, Schock J, Cronin M. Quantitation of human immunodefciency virus type 1 RNA in plasma by using blood dried on flter paper. J. Clin. Microbiol. 36(1), 258-260 (1998). (Pubitemid 28047472)
27. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, de Mendoza C Correlation between human immunodefciency virus type 1 (HIV-1) RNA measurements obtained with dried-blood spots and those obtained with plasma by use of NucliSENS® EasyQ HIV-1 and Abbott RealTime HIV load tests. J. Clin. Microbiol. 47(4), 1031-1036 (2009).
28. Ikomey GM, Atashili J, Okomo-Assoumou MC, Mesembe M, Ndumbe PM. Dried-blood spots versus plasma for the quantifcation of HIV-1 RNA using the manual (PCR-ELISA) amplicor monitor HIV-1 version 1.5 assay in Yaounde, Cameroon. J. Int. Assoc Physicians AIDS Care (Chic Ill) 8(3), 181-184 (2009).
29. Johannessen A, Garrido C, Zahonero N et al. Dried-blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin. Infect. Dis. 49(6), 976-981 (2009).
30. Kane CT, Ndiaye HD, Diallo S et al. Quantitation of HIV-1 RNA in dried-blood spots by the real-time NucliSENS® EasyQ HIV-1 assay in Senegal. J. Virol. Methods 148(1-2), 291-295 (2008).
31. Leelawiwat W, Young NL, Chaowanachan T et al. Dried-blood spots for the diagnosis and quantitation of HIV-1: stability studies and evaluation of sensitivity and specifcity for the diagnosis of infant HIV-1 infection in Thailand. J. Virol. Methods 155(2), 109-117 (2009).
32. Lira R, Valdez-Salazar H, Vazquez-Rosales G et al. Genotypic testing for HIV-1 drug resistance using dried-blood samples. Arch. Virol. 155(7), 1117-1125 (2010).
33. Lofgren SM, Morrissey AB, Chevallier CC et al. Evaluation of a dried-blood spot HIV-1 RNA program for early-infant diagnosis and viral-load monitoring at rural and remote healthcare facilities. AIDS 23(18), 2459-2466 (2009).
34. Marconi A, Balestrieri M, Comastri G et al. Evaluation of the Abbott real-time HIV-1 quantitative assay with dried-blood spot specimens. Clin. Microbiol. Infect. 15(1), 93-97 (2009).
35. Mbida AD, Sosso S, Flori P et al. Measure of viral load by using the Abbott real-time HIV-1 assay on dried-blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. J. Acquir. Immune Defc Syndr 52(1), 9-16 (2009).
36. Mehta N, Trzmielina S, Nonyane BA et al. Low-cost HIV-1 diagnosis and quantifcation in dried-blood spots by real time PCR. PLoS One 4(6), e5819 (2009).
37. Monleau M, Montavon C, Laurent C et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodefciency virus type 1 RNA quantifcation and PCR amplifcation for drug resistance testing. J. Clin. Microbiol. 47(4), 1107-1118 (2009).
38. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantifcation and PCR amplifcation for drug resistance genotyping. J. Antimicrob. Chemother. 65(8), 1562-1566. (2010).
39. O'Shea S, Mullen J, Corbett K, Chrystie I, Newell ML, Banatvala JE. Use of dried whole-blood spots for quantifcation of HIV-1 RNA. AIDS 13(5), 630-631 (1999). (Pubitemid 29286736)
40. Reigadas S, Schrive MH, urillac-Lavignolle V, Fleury HJ. Quantitation of HIV-1 RNA in dried-blood and plasma spots. J. Virol. Methods 161(1), 177-180 (2009).
41. Uttayamakul S, Likanonsakul S, Sunthornkachit R et al. Usage of dried-blood spots for molecular diagnosis and monitoring HIV-1 infection. J. Virol. Methods 128(1-2), 128-134 (2005). (Pubitemid 40980218)
42. Waters L, Kambugu A, Tibenderana H et al. Evaluation of flter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J. Acquir. Immune Defc Syndr. 46(5), 590-593 (2007). (Pubitemid 350191052)
43. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purifcation of nucleic acids. J. Clin. Microbiol. 28(3), 495-503 (1990). (Pubitemid 20078123)
44. Bruisten S, van Gemen B, Koppelman M et al. Detection of HIV-1 distribution in different blood fractions by two nucleic acid amplifcation assays. AIDS Res. Hum. Retroviruses 9(3), 259-265 (1993). (Pubitemid 23108521)
45. van Gemen B, Wiel P, van Beuningen R et al. The one-tube quantitative HIV-1 RNA NASBA: precision, accuracy and application. PCR Methods Appl. 4(4), S177-S184 (1995).
46. Hirsch MS, Gunthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47(2), 266-285 (2008). (Pubitemid 351920631)
47. National Department of Health. National Antiretroviral Treatment Guidelines. Department of Health, Johannesburg, South Africa (2004).
48. Amellal B, Katlama C, Calvez V. Evaluation of the use of dried spots and of different-storage conditions of plasma for HIV-1 RNA quantifcation. HIV Med. 8(6), 396-400 (2007). (Pubitemid 47163272)
49. Bertagnolio S, Soto-Ramirez L, Pilon R et al. HIV-1 drug resistance surveillance using dried whole-blood spots. Antivir. Ther. 12(1), 107-113 (2007). (Pubitemid 46340432)
50. Buckton AJ, Bissett SL, Myers RE et al. Development and optimization of an internally controlled dried-blood spot assay for surveillance of human immunodefciency virus type-1 drug resistance. J. Antimicrob. Chemother. 62(6), 1191-1198 (2008).
51. Garcia-Lerma JG, McNulty A, Jennings C, Huang D, Heneine W, Bremer JW Rapid decline in the effciency of HIV drug-resistance genotyping from dried-blood spots (DBS) and dried-plasma spots (DPS) stored at 37 °C and high humidity. J. Antimicrob. Chemother. 64(1), 33-36 (2009).
52. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried-blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay J. Clin. Virol. 41(4), 283-287 (2008).
53. Hearps AC, Ryan CE, Morris LM, Plate MM, Greengrass V, Crowe SM. Stability of dried-blood spots for HIV-1 drug resistance analysis. Curr. HIV Res. 8(2), 134-140 (2010).
54. Johannessen A, Holberg-Petersen M, Lövgården G et al. HIV-1 drug-resistance testing on dried-blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania. Antivir. Ther. 15, DOI:10.3851/IMP1660 (2010) (Epub ahead of print).
55. Masciotra S, Garrido C, Youngpairoj AS et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried-blood spots in antiretroviral-experienced patients. AIDS 21(18), 2503-2511 (2007). (Pubitemid 350145182)
56. McNulty A, Jennings C, Bennett D et al. Evaluation of dried-blood spots for human immunodefciency virus type 1 drug resistance testing. J. Clin. Microbiol 45(2), 517-521 (2007).
57. Steegen K, Luchters S, Demecheleer E et al. Feasibility of detecting human immunodefciency virus type 1 drug resistance in DNA extracted from whole blood or dried-blood spots. J. Clin. Microbiol. 45(10), 3342-3351 (2007). (Pubitemid 47585660)
58. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG. HIV-1 drug resistance genotyping from dried-blood spots stored for 1 year at 4°C. J. Antimicrob. Chemother. 61(6), 1217-1220 (2008). (Pubitemid 351753584)
59. Ziemniak C, George-Agwu A, Moss WJ, Ray SC, Persaud D. A sensitive genotyping assay for detection of drug-resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried-blood spots or frozen RNA extracts. J. Virol. Methods 136(1-2), 238-247 (2006). (Pubitemid 44051599)
60. Bi X, Gatanaga H, Ida S et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood-mononuclear cells by more than a year. J. Acquir. Immune Defc Syndr. 34(1), 1-6 (2003). (Pubitemid 37100105)
61. Venturi G, Romano L, Carli T et al. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir. Ther. 7(4), 245-250 (2002). (Pubitemid 36427128)
62. Nelson JA, Loftis AM, Kamwendo D et al. Nevirapine resistance in human immunodefciency virus type 1-positive infants determined using dried-blood spots stored for up to 6 years at room temperature. J. Clin. Microbiol. 47(4), 1209-1211 (2009).
63. Garrido C, Zahonero N, Fernandes D et al. Subtype variability, virological response and drug resistance assessed on dried-blood spots collected from HIV patients on antiretroviral therapy in Angola. J. Antimicrob. Chemother. 61(3), 694-698 (2008). (Pubitemid 351321149)
64. Bertagnolio S, Derdelinckx I, Parker M et al. World Health Organization/HIVResNet. Drug resistance laboratory strategy. Antivir. Ther. 13(Suppl 2), 49-57 (2008).
65. Kamoto K, Berle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir. Ther. 13(Suppl. 2), 83-87 (2008). (Pubitemid 352019093)
66. Somi GR, Kibuka T, Diallo K et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir. Ther. 13(Suppl 2), 77-82 (2008). (Pubitemid 352019092)
67. Mousavi SM, Hamkar R, Gouya MM et al. Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study. Arch. Virol. 155(3), 329-334 (2010).
68. Zhang J, Kang D, Fu J et al. Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed HIV type 1-infected patients in Shandong Province, China. AIDS Res. Hum. Retroviruses 26(1), 99-103 (2010).
69. Behets F, Kashamuka M, Pappaioanou M et al. Stability of human immunodefciency virus type 1 antibodies in whole-blood dried on flter paper and stored under various tropical conditions in Kinshasa, Zaire. J. Clin. Microbiol. 30(5), 1179-1182 (1992).
70. + lymphocyte counts in HIV-1-infected patients. Lancet 362(9394), 1459-1460 (2003). (Pubitemid 37352885)
71. Koal T, Burhenne H, Romling R, Svoboda M, Resch K, Kaever V. Quantifcation of antiretroviral drugs in dried-blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19(21), 2995-3001 (2005). (Pubitemid 41540724)
72. Malm M, Romsing S, Obua C, Bergqvist Y. Determination of lamivudine, zidovudine and nevirapine in capillary blood sampled on flter paper by LC. J. Chromatogr. Sci. 47(10), 855-862 (2009).
73. Buckton AJ, Prabhu DP, Cane PA, Pillay D. No evidence for cross-contamination of dried-blood spots excised using an offce hole-punch for HIV-1 drug resistance genotyping. J. Antimicrob. Chemother. 63(3), 615-616 (2009).
74. Lee HH, Dineva MA, Chua YL, Ritchie AV, Ushiro-Lumb I, Wisniewski CA. Simple amplifcation-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. J. Infect. Dis. 201(Suppl 1), S65-S72 (2010).